Cipla announced that a routine current Good Manufacturing Practices (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at manufacturing facility of the Company located
in Kurkumbh, Maharashtra, India from 29 April 2024 to 8 May 2024. On conclusion of the inspection, the Company has received 1 inspectional observation in Form 483.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
